Simulands builds tools that enable cardiologists and echocardiographers to train in performing complex cardiovascular interventional procedures risk-free using human-grade simulators. Their human-grade simulators are medical-grade, ISO-compliant simulators. They are offering procedure experience that provide real haptic responses, actual procedural imaging guidance, true understanding of device performance, catering to a wide range of experience and knowledge levels.
Due to Simulands’ expertise and understanding of the medical practice, the Zurich-based company, which was founded in 2019 and has grown rapidly since then, and has already established itself as a leading provider of medical simulation training in the field of structural cardiac interventions. As a result, the company can count among its clientele large and well-known MedTech companies, including Abbott Laboratories, Edwards Lifesciences, Boston Scientific, as well as many others including innovative up and coming startups in the field, who use the simulators for physician training and to internally train their field specialists.
“With the investment into Simulands AG, we are pleased to make our first investment from our newly launched sixth fund generation. With our investment, we specifically want to drive the expansion of the product portfolio as well as the international expansion. For our new fund, we seek for further innovative, fast-growing healthcare companies that can make a real difference in healthcare,” explains SHS partner Dr. Cornelius Maas.
Andrea Guidotti, CEO of Simulands, adds: “Partnering with SHS is an invaluable opportunity for Simulands to accelerate its entry to key global markets expanding support to its customers base. SHS’ expertise and proven track record of excellence in the healthcare sector will further consolidate our growth and accelerate the progress towards our long-term vision.”
(Press release / SK)